The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer

Diagnostic Pathology

Xiaowu Li¹  Xi Zhang²  Kai Chen²  Guo Wu²  Peng Jiang²  Zhonghu Li²  Yingqiang Xu² 

[1] No.30 Gaotanyan Street, Shapingba District, Chongqing 400038, China;Department of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China

关键词: Pancreatic cancer;    Prognosis;    ECM;    TN-C;    MMP-9;   

Others  :  1235140
DOI  :  10.1186/s13000-015-0445-3

 received in 2015-10-04, accepted in 2015-11-28,  发布年份 2015

【 摘 要 】

Background

Matrix metalloproteinase-9 (MMP-9) and Tenascin-C (TN-C) have been shown to be involved in the metastasis of many tumors. The purpose of this study was to determine the relationship between the co-expression of these two molecules and the clinical prognosis of pancreatic cancer.

Methods

We investigated the expression of TN-C and MMP-9 in 103 pancreatic cancer tissues by immunohistochemistry and used statistical analyses to investigate the correlations of individual expression or co-expression of these two molecules with clinicopathological parameters and survival of pancreatic cancer.

Results

The expression of MMP-9 and TN-C were increased in pancreatic cancer. The co-expression of MMP-9 and TN-C was also detected. The expression of MMP-9 and TN-C were correlated with vascular invasion, lymph node invasion, liver metastases and TNM stage. The co-expression of MMP-9 and TN-C was significantly related to the pancreatic cancer metastases. The individual overexpression of MMP-9 or TN-C significantly decreased the overall survival rates. The co-expression of MMP-9 and TN-C had the lowest overall survival rates. The co-expression of MMP-9 and TN-C was an independent predictor of survival for pancreatic cancer patients.

Conclusions

Co-expression of MMP-9 and TN-C was associated with poorer prognosis and was found to be an independent predictor of survival.

【 授权许可】

   
2015 Xu et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK et al.. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013; 63(5):318-48.
• [2]Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol. 2008; 40(6-7):1101-10.
• [3]Wong GS, Rustgi AK. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer. 2013; 108(4):755-61.
• [4]Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009; 3(3-4):287-310.
• [5]Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67.
• [6]Nakamura-Ishizu A, Okuno Y, Omatsu Y, Okabe K, Morimoto J, Uede T et al.. Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration. Blood. 2012; 119(23):5429-37.
• [7]Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol. 2005; 37(5):1066-83.
• [8]Trebaul A, Chan EK, Midwood KS. Regulation of fibroblast migration by tenascin-C. Biochem Soc Trans. 2007; 35(Pt 4):695-7.
• [9]Chen J, Chen Z, Chen M, Li D, Li Z, Xiong Y et al.. Role of fibrillar Tenascin-C in metastatic pancreatic cancer. Int J Oncol. 2009; 34(4):1029-36.
• [10]Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer. 2002; 98(3):362-9.
• [11]Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K et al.. Tenascin-C expression correlates with prognosis in gastric cancer. Oncology. 2003; 64(3):245-50.
• [12]Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K et al.. Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res. 1993; 55(3):295-7.
• [13]Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Bohling T. Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol. 2005; 58(3):297-300.
• [14]Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Gene Dev. 2000; 14(2):163-76.
• [15]Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000; 10(6):415-33.
• [16]Lekstan A, Lampe P, Lewin-Kowalik J, Olakowski M, Jablonska B, Labuzek K et al.. Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma. J Physiol Pharmacol. 2012; 63(6):589-99.
• [17]Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9.
• [18]Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res. 1995; 1(9):1035-41.
• [19]Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H et al.. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol. 2004; 57(9):927-31.
• [20]Kaariainen E, Nummela P, Soikkeli J, Yin M, Lukk M, Jahkola T et al.. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol. 2006; 210(2):181-91.
• [21]To WS, Midwood KS. Identification of novel and distinct binding sites within tenascin-C for soluble and fibrillar fibronectin. J Biol Chem. 2011; 286(17):14881-91.
• [22]To WS, Midwood KS. Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis. Matrix Biol. 2010; 29(7):573-85.
• [23]Sullivan MM, Barker TH, Funk SE, Karchin A, Seo NS, Hook M et al.. Matricellular hevin regulates decorin production and collagen assembly. J Biol Chem. 2006; 281(37):27621-32.
• [24]Asokananthan N, Lan RS, Graham PT, Bakker AJ, Tokanovic A, Stewart GA. Activation of protease-activated receptors (PARs)-1 and -2 promotes alpha-smooth muscle actin expression and release of cytokines from human lung fibroblasts. Physiol Rep. 2015;3(2). doi:10.14814/phy2.12295.
• [25]Rao KB, Malathi N, Narashiman S, Rajan ST. Evaluation of myofibroblasts by expression of alpha smooth muscle actin: a marker in fibrosis, dysplasia and carcinoma. J Clin Diagn Res. 2014; 8(4):ZC14-7.
• [26]Yeung TL, Leung CS, Mok SC. CAF reprogramming inhibits ovarian cancer progression. Cell cycle. 2014; 13(24):3783-4.
• [27]Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006; 20(2):197-209.
• [28]Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T et al.. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer. 2001; 92(6):1419-26.
• [29]Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K et al.. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer. 1998; 78(11):1507-13.
• [30]Pilch H, Schaffer U, Schlenger K, Lautz A, Tanner B, Hockel M et al.. Expression of tenascin in human cervical cancer--association of tenascin expression with clinicopathological parameters. Gynecol Oncol. 1999; 73(3):415-21.
• [31]Juuti A, Nordling S, Louhimo J, Lundin J, Haglund C. Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol. 2004; 57(11):1151-5.
• [32]Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D et al.. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res. 2003; 9(13):4935-43.
• [33]Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD et al.. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res. 1999; 5(1):25-33.
• [34]Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000; 6(7):2726-34.
• [35]Gardian K, Janczewska S, Durlik M. Microenvironment elements involved in the development of pancreatic cancer tumor. Gastroenterol Res Pract. 2012; 2012:585674.